Keeping the
momentum going
Background video
Animated canvas: two scientists at work; a smiling young woman cares for a man in a wheelchair.
Investing for future generations
Dr. Reddy’s Biologics is actively investing in a better, healthier tomorrow through our robust biologics and biosimilars pipelines.
Whether it’s through innovation or investment, our unwavering goal is to work with our partners to bring about the most positive impact for patients.
Our most recent opportunity to make a meaningful difference is happening at our new US-based Biologics division.
Our pipeline of biosimilar assets across therapeutic and biologic areas
2024-2027
Rheumatology – Rituximab
(licensed to Fresenius Kabi);
Denosumab;
Abatacept
Oncology – Denosumab
Rare Disease/ALS – COYA 302
2028-2030
Oncology – 4
Rheumatology – 3
Dermatology – 1
2031-2034
Oncology – 4
Dermatology – 1
Hematology – 1
2034+
Oncology – 1
Hematology – 1
The information contained in this chart was current as of its date of publication. While this pipeline chart remains on the company’s website the company assumes no duty to update the information to reflect subsequent developments. Consequently, the company will not update the information contained in the pipeline chart and investors should not rely upon the information as current or accurate after its date of publication.